Palynziq (pegvaliase), new treatment for phenylketonuria, a rare inherited metabolic disease
EMA’s human medicines committee (CHMP) has recommended the authorisation of…
Zynquista (sotagliflozin), New add-on treatment to insulin for treatment of certain patients with type 1 diabetes
EMA’s human medicines committee (CHMP) has adopted a positive opinion for…
The World Health Organisation issues an alert on falsified ICLUSIG traded globally
The Medical Product Alert relates to confirmed falsified versions of ICLUSIG…
Forxiga and Edistride (Dapagliflozin) recommended by EMA as first oral add-on treatment to insulin for treatment of certain patients with type 1 diabetes
EMA’s human medicines committee (CHMP) has recommended for the first time an…
Cablivi (caplacizumab-yhdp) approved by FDA for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP)
The U.S. Food and Drug Administration has approved Cablivi (caplacizumab-yhdp)…
First generic version of Sabril (vigabatrin) approved by FDA for the treatment of complex partial seizures
The U.S. Food and Drug Administration approved the first generic version of…
Ultomiris (ravulizumab), approved by FDA for the treatment of paroxysmal nocturnal hemoglobinuria (PNH)
The U.S. Food and Drug Administration has approved Ultomiris (ravulizumab)…
European Commission Approves Merck’s DELSTRIGO (doravirine / lamivudine / tenofovir disoproxil fumarate), a Once-Daily Fixed-Dose Combination Tablet as a Complete Regimen for the Treatment of HIV-1 in Appropriate Patients
Delstrigo is an antiviral medicine used to treat adults infected with human…
FDA approves Elzonris (tagraxofusp-erzs), first treatment for rare blood disease
The U.S. Food and Drug Administration has approved Elzonris (tagraxofusp-erzs)…